E-DRUG: Alternatives for the patent system? (2)
------------------------------------------------
dear E-druggers,
One of the other available alternatives is the system which was used (I don't know exactly about the present situation) in countries with a social insurance system where the registration and the reimbursement systems are closely linked, such as France and Belgium. It may then be possible to negotiate the price with the manufacturer before the drug is released on the market. The price can then be based on the real cost of developing and marketing this particular drug, and the manufacturer can be requested to open its books. If that is the case the price cannot be used to cover eventual losses on other drugs or unrealistic developing expenses
for future drugs.
Best regards,
Dr L Offerhaus
Netherlands
offerhausl@euronet.nl